Researchers at the Leiden University Medical Center (LUMC) have announced promising early results from a clinical trial using lab-grown...

VarmX has received IND approval for its Phase 3 trial of VMX‑C001, a recombinant factor X variant designed to neutralize FXa‑inhibiting anticoagulants during emergency surgery. Backed by robust Phase 1 data and boosted by a €15 million EIC investment, this step positions VMX‑C001 to meet a gap in urgent haemostasis care.

𝗛𝗼𝘄 𝗱𝗼 𝘄𝗲 𝘁𝘂𝗿𝗻 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝗳𝗶𝗰 𝗸𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲 𝗶𝗻𝘁𝗼 𝗿𝗲𝗮𝗹 𝘀𝗼𝗹𝘂𝘁𝗶𝗼𝗻𝘀, 𝗳𝗮𝘀𝘁𝗲𝗿, 𝘀𝗺𝗮𝗿𝘁𝗲𝗿, 𝗮𝗻𝗱 𝘁𝗼𝗴𝗲𝘁𝗵𝗲𝗿? That’s the question Key Region Leiden is working to answer....

On July 3, 2025, Progress – Experts in Life Sciences announced its acquisition of Methnani & Associates, a consultancy specialised in pharmaceutical microbiology and sterility assurance. The move strengthens Progress’s position in the field of quality and regulatory services for life sciences, with an emphasis on GMP compliance and contamination control. 

On June 1, 2025, the Leiden University Medical Center (LUMC) officially opened its Post-COVID Expertise Centre, strengthening its role in national...

A decade of change at Leiden Bio Science Park has been captured in a newly released publication: Campus in Bloom – Stories of Growth, Connection and...

Peter Lindenburg winnaar VUURVLIEGEN tijdens Dutch Bio Science Week Den Haag, 4 juli 2025 – Bijna 130 leerlingen van vier basisscholen uit de Leidse...

Dutch Bio Science Week 2025 has brought an extraordinary buzz to Leiden, transforming the city and the Bio Science Park into a hub of discovery,...

The Court of Audit visited LBSP to explore how science and entrepreneurship create public value, with stops at TNO, Peregrion, NTrans, and VarmX sparking discussion on biotech innovation.